Altimmune (LTS:0A4C) Beginning Cash Position : $36.97 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Altimmune Beginning Cash Position?

Altimmune's Beginning Cash Position for the quarter that ended in Mar. 2025 was $36.97 Mil.

Altimmune's quarterly Beginning Cash Position declined from Sep. 2024 ($57.17 Mil) to Dec. 2024 ($31.52 Mil) but then increased from Dec. 2024 ($31.52 Mil) to Mar. 2025 ($36.97 Mil).

Altimmune's annual Beginning Cash Position declined from Dec. 2022 ($190.34 Mil) to Dec. 2023 ($111.13 Mil) but then increased from Dec. 2023 ($111.13 Mil) to Dec. 2024 ($135.16 Mil).

Altimmune Beginning Cash Position Historical Data

The historical data trend for Altimmune's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Beginning Cash Position Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

9.00

115.95

190.34

111.13

135.16

Altimmune Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															135.16	79.02	57.17	31.52	36.97

Altimmune Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Altimmune Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Altimmune's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ALT:USA 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines